Get started
Author

Christopher Ryan Cahoon

Observed name: Christopher Cahoon
OpenAlex ID: A5115006515
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
2025 · James A. Davis, Jordan Snyder, et al. · Blood Cancer Journal · 12
Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
2025 · Surbhi Sidana, Brett Reid, et al. · Blood · 7
Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma
2025 · Jessica McElwee, Grace Elsey, et al. · Blood · 3
PDF
Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
2024 · James A Davis, Jordan Snyder, et al. · Blood · 3
PDF
Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies
2025 · Victoria Nachar, Iman Ahmed, et al. · Blood · 2
PDF
Enhancing the Safety of Ciltacabtagene Autoleucel in Relapsed Multiple Myeloma (MM):Identification of Potentially Modifiable Risk-Factors Associated with Delayed Neurotoxicity and Non-Relapse Mortality
2026 · Surbhi Sidana, Brett Reid, et al. · Transplantation and Cellular Therapy · 1
Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium
2025 · Eli Zolotov, Noa Biran, et al. · Blood · 1
Incidence of CMV-reactivation in multiple myeloma patients receiving bispecific antibodies
2025 · Jordan Snyder, Dennis Grauer, et al. · Blood · 1
PDF
Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium
2025 · Ran Reshef, Alexandria Jensen, et al. · Blood · 1
PDF
Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)
2025 · Danai Dima, Lauren Peres, et al. · Blood · 1
PA-086 Clinical and Biological Predictors of Durable Response to Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)
2026 · Gliceida M. Galarza Fortuna, Lekha Mikkilineni, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-096 Clinical Outcomes and Predictors of Survival in Central Nervous System (CNS) Multiple Myeloma: A Retrospective Cohort Study
2026 · Bita Bashy, Payton Utzman, et al. · Clinical Lymphoma Myeloma & Leukemia
Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
2026 · Jessica McElwee, Grace Elsey, et al. · American Journal of Hematology
Condensed vs. Standard Step‐Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma
2026 · Grace Elsey, James A. Davis, et al. · European Journal Of Haematology
PDF
Early Relapse after Ciltacabtagene Autoleucel in High-Risk Multiple Myeloma: Implications for Risk-Adapted Therapy and Clinical Trial Design
2026 · Doris K. Hansen, Lauren C Peres, et al. · Transplantation and Cellular Therapy
Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma
2025 · Doris Hansen, Lauren Peres, et al. · Blood
Works count: 16
Citation count: 32
H-index: 3
I10-index: 1
Year
Topic
Type